Milestone Pharmaceuticals (MIST) Non-Current Debt (2023 - 2026)

Milestone Pharmaceuticals (MIST) has reported Non-Current Debt for 4 consecutive years, with $59.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt rose 7.19% year-over-year to $59.2 million; the trailing twelve-month figure through Jun 2026 stood at $59.2 million (up 7.19% YoY), and the FY2025 full-year result was $57.2 million, up 7.2% from the prior year.
• Non-Current Debt grew to $59.2 million in Q2 2026 per MIST's latest filing, from $58.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $59.2 million in Q2 2026 and bottomed at $47.3 million in Q1 2023.
• Historically, Non-Current Debt has averaged $53.0 million across 4 years, with a median of $52.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt advanced 7.02% in 2024, then grew 7.2% in 2025.
• Over 4 years, Non-Current Debt stood at $49.8 million in 2023, then increased by 7.19% to $53.4 million in 2024, then advanced by 7.2% to $57.2 million in 2025, then advanced by 3.53% to $59.2 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $59.2 million, $58.2 million, and $57.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.